Effects of Orally Administered Bacteria Carrying HIF-1α Gene in an Experimental Model of Intestinal Ischemia

Archives of Medical Research

Volumn 41, Issue 5, 2010, Pages 332-337

  Gardlik, Roman ^a   Hodosy, Julius ^a   Palffy, Roland ^a   Behuliak, Michal ^a   Janega, Pavol ^a,b   Celec, Peter ^a,c  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c Physics and Informatics   (Slovakia)

Author keywords

Bactofection; Beta integrin; Gene delivery; HIF 1 ; Intestinal ischemia

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ESCHERICHIA COLI; GENE DELIVERY SYSTEM; GENE EXPRESSION; INTESTINE ISCHEMIA; MALE; NONHUMAN; OXIDATIVE STRESS; RAT;

ADMINISTRATION, ORAL; ANIMALS; BACTERIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTESTINES; ISCHEMIA; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 77956837241     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.07.009     Document Type: Article

References (14)

1. Heinl-Green A., Radke P.W., Munkonge F.M., et al. The efficacy of a master switch gene HIF-1alpha in a porcine model of chronic myocardial ischaemia. Eur Heart J 2005, 26:1327-1332.
2. Patel T.H., Kimura H., Weiss C.R., et al. Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 2005, 68:144-154.
3. Tal R., Shaish A., Rofe K., et al. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Mol Ther 2008, 16:1927-1936.
4. Rajagopalan S., Olin J., Deitcher S., et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007, 115:1234-1243.
5. Pajusola K., Kunnapuu J., Vuorikoski S., et al. Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 2005, 19:1365-1367.
6. Gardlik R., Palffy R., Hodosy J., et al. Vectors and delivery systems in gene therapy. Med Sci Monit 2005, 11:RA110-121.
7. Palffy R., Gardlik R., Hodosy J., et al. Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther 2006, 13:101-105.
8. Chachami G., Paraskeva E., Georgatsou E., et al. Bacterially produced human HIF-1alpha is competent for heterodimerization and specific DNA-binding. Biochem Biophys Res Commun 2005, 331:464-470.
9. Celec P., Gardlik R., Palffy R., et al. The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor-an alternative gene therapy. Med Hypotheses 2005, 64:505-511.
10. Morote-Garcia J.C., Rosenberger P., Nivillac N.M., et al. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 2009, 136:607-618.
11. Kelly B.D., Hackett S.F., Hirota K., et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003, 93:1074-1081.
12. Critchley-Thorne R.J., Stagg A.J., Vassaux G. Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination. Mol Ther 2006, 14:183-191.
13. Hartmann H., Eltzschig H.K., Wurz H., et al. Hypoxia-independent activation of HIF-1 by enterobacteriaceae and their siderophores. Gastroenterology 2008, 134:756-767.
14. Sugase K., Landes M.A., Wright P.E., et al. Overexpression of post-translationally modified peptides in Escherichia coli by co-expression with modifying enzymes. Protein Expr Purif 2008, 57:108-115.